Monte Rosa Therapeutics
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms t...
Latest News
2 months ago · seekingalpha.com
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk TranscriptMonte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
2 months ago · benzinga.com
Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular DiseaseMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) reported Phase 1 trial results for its inflammatory disease drug candidate MRT-8102, while outlining plans to advance the treatment into multiple Phase 2 studies.
2 months ago · seekingalpha.com
Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance SheetMonte Rosa Therapeutics is rated a risky Buy, with valuation hinging on the clinical success and milestone payments from its outlicensed flagship asset MRT-6160. MRT-6160, targeting autoimmune diseases, offers differentiated safety and oral convenience, with Phase 2 results as the key near-term catalyst for GLUE. GLUE maintains a robust $626 million cash position, providing a 3.5-year runway and cushioning downside risk amid high clinical trial expenses.
3 months ago · globenewswire.com
Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesBOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D.
3 months ago · zacks.com
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue EstimatesMonte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.15 per share a year ago.
5 months ago · fool.com
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a year of exceptional share price gains.
5 months ago · seekingalpha.com
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform PotentialMonte Rosa Therapeutics, Inc. is a leading biotech in molecular glue degraders, with a $1.45bn valuation and robust partnerships with Novartis and Roche. GLUE's pipeline shows promising Phase 1 data, especially for MRT-8102 and MRT-6160, but lacks Phase 2 proof-of-concept results to fully derisk programs. Significant cash runway ($675m) and milestone-rich deals provide operational security while awaiting pivotal clinical readouts and potential Novartis milestones.
6 months ago · zacks.com
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue EstimatesMonte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.57 per share a year ago.
7 months ago · fool.com
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital RaiseA GLUE executive disposed of 8,000 shares for a transaction value of approximately $141,000 at a weighted average price of around $17.64 per share on April 14, 2026. The sale represented 1.30% of their direct common stock holdings, reducing their directly held common shares from 613,471 to 605,471.
8 months ago · zacks.com
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Monte Rosa Therapeutics (GLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove GLUE